Related Experiment Video
Updated: May 5, 2026
Use of Rabbit Eyes in Pharmacokinetic Studies of Intraocular Drugs
Published on: July 23, 2016
Intravitreal dexamethasone implant in epiretinal membrane-associated diabetic macular edema refractory to anti-VEGF
S Nalcaci1, H H Gobeka, K Sincar
1Department of Ophthalmology, Faculty of Medicine, Ege University, Izmir, Türkiye.
Objective:
The aim of the study was to report clinical outcomes of intravitreal dexamethasone (DEX) implant in patients with epiretinal membrane (ERM)-associated diabetic macular edema (DME) unresponsive to intravitreal ranibizumab (IVR).
Materials And Methods:
11 eyes of type 2 diabetes patients >18 years old with ERM-associated DME unresponsive to ≥3 IVR injections were included. Patients with central macular thickness (CMT) >300 µm following a single dose DEX implant between January 2021 and December 2023, suggesting unresponsiveness or poor response, were retrospectively evaluated. A full ophthalmologic examination was performed pre- and first-to-sixth month post-therapy, including measuring best-corrected visual acuity (BCVA), intraocular pressure (IOP), and retinal ultra-structural parameters like CMT, central 1 mm retinal thickness (RT), and central macular volume (CMV).
Results:
The mean age was 66.50±5.01 years. BCVA increased considerably in the first two months (p<0.050) compared to pre-therapy. Changes in CMT, RT, and CMV were statistically significant for ≥4 months for CMT, five months for RT, and six months for CMV (p<0.050). Increased BCVA coincided with retinal ultra-structural healing throughout the same period. Most patients had predominantly normal IOPs. Anti-glaucoma medication was initiated in just three patients where IOPs were >25 mmHg.
Conclusions:
DEX implant could be a reliable and effective therapeutic alternative for ERM-associated DME resistant to anti-VEGFs, particularly during the first 3 months of treatment, when it appears to be most effective. A single DEX implant can produce a satisfactory and reasonably safe response, and the treatment can be repeated even after the implant's potency has gradually declined. Importantly, improved BCVA and retinal ultra-structure following DEX implant could lessen the need for ERM surgery and multiple intravitreal anti-VEGF injections. If ERM-associated DME persists despite multiple DEX implants, surgery should be considered.
